Tarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding.
The numbers were unambiguous. Q1 EPS came in at -$0.16, beating the -$0.33 estimate by $0.17. Revenue of $162.1 million topped the $148.4 million consensus. Management reaffirmed full-year 2026 guidance of $670-700 million in XDEMVY net product sales and reiterated peak sales potential exceeding $2 billion. For a company whose bear case rests squarely on whether XDEMVY can grow into its commercial promise, those figures land hard against the skeptics.
Short interest tells a story that was already turning before tonight's print. At 10.6% of free float, the position is meaningful — but the direction of travel has been consistently lower. Shorts have trimmed roughly 10.6% of their exposure over the past month, with the pace of reduction accelerating this week at about 2.5%. The ORTEX short score has drifted from 59.7 a week ago to 57.7 now — still elevated, but moving in the wrong direction for the bears. Borrow costs are negligible at 0.41% annually, and availability remains extremely loose, meaning no mechanical squeeze pressure is building. The reduction in short interest looks like voluntary profit-taking or capitulation, not a forced unwind.
Options positioning leans defensive, though not alarmingly so. The put/call ratio at 1.68 runs above its 20-day average of 1.48, placing it just 0.6 standard deviations above the mean. The ratio has held in a tight band since mid-April — roughly 1.67 to 1.72 — after jumping from around 1.07 in early April. That earlier shift likely reflected pre-earnings hedging. The z-score being only moderately elevated suggests the options market had concerns but did not price in a disaster scenario ahead of the print.
The Street remains broadly constructive. HC Wainwright reiterated its Buy with an $88 target on May 4 — the day before earnings — and earlier in February both Oppenheimer and Guggenheim raised their targets to $105 and $90 respectively, both maintaining top-line positive ratings. Goldman Sachs holds the most cautious stance with a Neutral and a $51 target, though that figure looks increasingly stale against a stock trading at $65 and reporting accelerating revenue growth. The mean consensus target of $94 implies roughly 45% upside from current levels. Valuation multiples have compressed sharply: the PE ratio has dropped roughly 192 points over 30 days, and EV/EBITDA has fallen 116 points over the same window — a reflection of earnings estimates being revised upward faster than the stock has moved.
Institutional ownership adds a further supportive layer. BlackRock holds 8.9%, Vanguard 5.6%, and a cluster of specialist healthcare funds — RTW Investments, Deep Track Capital, and Paradigm Biocapital — collectively control more than 20% of shares. Recent 13G filings show Jennison Associates filing a 13G/A today, and incremental adds from Geode, Assenagon, and Driehaus in recent weeks. Insider activity from mid-March involved a coordinated round of small sells across the C-suite including the CEO, CFO, and COO — all at $67, modestly above today's $65.04 close. The net 90-day insider position remains positive in aggregate at roughly 107,000 shares net added, with $7.3 million in net proceeds dominated by option-related transactions. The cluster of March sells is a standard diversification pattern at elevated prices rather than a red-flag exodus.
With Q2 earnings now pencilled in for June 25, the next catalyst is straightforward: can XDEMVY's quarterly run-rate support the $670-700 million full-year guide? Q1 delivered $162 million — annualised, that puts the guidance range comfortably within reach if the growth trajectory holds, and tonight's beat sets the bar for what the Street will expect when Tarsus reports again.
See the live data behind this article on ORTEX.
Open TARS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
